Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance ...

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

New research reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Experts urge ...

A new study has found that a diabetes medicine called tirzepatide can help people lower their blood sugar and lose weight ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

The drugmaker plans to launch Semaglutide in 87 countries next year, including those where patents are expiring and emerging ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effects DehydraTECH reduces side effects and could support patient ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...